Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Receivables (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Change in Receivables data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Change in Receivables rose 157.88% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $12.5 million, up 283.34%, while the annual FY2024 figure was -$2.3 million, 641.36% down from the prior year.
  • Change in Receivables reached $4.8 million in Q3 2025 per PLX's latest filing, up from $4.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.1 million in Q2 2024 and bottomed at -$8.4 million in Q3 2024.
  • Average Change in Receivables over 5 years is $637105.3, with a median of $2.3 million recorded in 2025.
  • Peak YoY movement for Change in Receivables: skyrocketed 254.98% in 2023, then tumbled 294.5% in 2024.
  • A 5-year view of Change in Receivables shows it stood at -$3.0 million in 2021, then tumbled by 47.81% to -$4.5 million in 2022, then grew by 16.41% to -$3.8 million in 2023, then surged by 120.0% to $752000.0 in 2024, then surged by 544.81% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $4.8 million in Q3 2025, $4.6 million in Q2 2025, and $2.3 million in Q1 2025.